



Welcome to the Tennessee Oncology DDU Open House

January 22, 2026

Bringing Phase 1 research to community oncology practices

 GRECO-
HAINSWORTH
CENTERS FOR RESEARCH

TENNESSEE
ONCOLOGY

“I learned that a clinical trial was an incredible opportunity for me to get access to treatment that might otherwise not be available to me for years”

– TNBC Research Patient

The History of GHCR

The Greco-Hainsworth Tennessee Oncology Centers for Research (GHCR) is Tennessee Oncology's dedicated clinical research division. Named to honor Drs. Anthony Greco and John Hainsworth, who founded Tennessee Oncology's original research arm in 1993, GHCR continues Tennessee Oncology's 40+ year legacy of groundbreaking cancer care innovation.




F. Anthony Greco, M.D.



John Hainsworth, M.D.

2025 Early Phase Program Milestones



“Even if the trial doesn’t help me, maybe it will help others down the line.”

- Extensive-Stage SCLC Research Patient



Drug Development Unit Capabilities


Phase 1 Capabilities

- Bispecifics/CAR T (admit/hospitalize for CRS management)
- RLT (in development for 2026)
- Oncolytic Viruses
- Prolonged PKs – up to 12 hrs, admit PRN
- Research biopsies / Injectables
- Multiple sub-specialists
- Dedicated Phase 1 Staffing

Facility

- 12 exam rooms, 1 injection room
- 4 dedicated PK rooms
- 14 infusion chairs, 2 private infusion rooms
- Hot Lab / RLT Processing


Lobby and Medical Assistant Station



PK Rooms & Exam Rooms



TENNESSEE
ONCOLOGY



DDU Lab



TENNESSEE
ONCOLOGY





TENNESSEE
ONCOLOGY

**“Joining a treatment study gives me
hope for tomorrow.”**

- Melanoma Research Patient



Infusion Area



TENNESSEE
ONCOLOGY



Research Lab: Kit Storage





Research Lab: Processing Benches, Centrifuges and Freezers



Research Pharmacy: USP 797/800 Hazardous IP Compounding Space





Research Pharmacy: USP 797/800 Non-hazardous IP
Compounding Space and Ante Room



Research Pharmacy: Hazardous and Non-hazardous IP storage spaces equipped with room temperature, refrigerated, -20 freezer, and -80 freezer IP storage spaces

HOT LAB

Aug 111

Hot Lab (coming 2026)



TENNESSEE
ONCOLOGY

“Love the staff. I’m treated very well here.”

- Extensive-stage SCLC Research Patient

Tennessee Oncology: Research Directors



Ian Flinn, MD, PhD
Chief Scientific Officer



Katy Beckermann, MD, PhD
Director of GU Research



Jesús Berdeja, MD
Director of Multiple
Myeloma Research



Mike Byrne, DO
Director of Cellular Therapy
Research, Lymphoma
Investigator



Brian Grieb, MD, PhD
Director of GI Research



Wade Iams, MD, MSCI
Director of Lung Cancer
Research



Sara Nunnery, MD, MSCI
Director of Breast Cancer
Research



Jeff Russell, MD, PhD, MBA
Director of Early Phase Research

Tennessee Oncology: Research Leadership




Jonathan Abbas, MD
Myeloid Investigator



Bertrand Anz, MD
Investigator, Heme
Malignancies




Will Donnellan, MD
Investigator, Heme
Malignancies



Constantine Logothetis, MD
Myeloid Investigator




Joseph Merriman, MD
Assistant Director of Early
Phase Research



Kent Shih, MD
Melanoma and CNS
Investigator

Tennessee Oncology: Far-Reaching Footprint



GHCR: Our Research Clinic Footprint



Nashville: Elliston Place Plaza (includes the DDU), Midtown Women's Health, Skyline, Southern Hills, Saint Thomas West

Chattanooga: Downtown, East, Med Park II, Memorial

GHCR: Cutting Edge Science in the Community

Community Research	Research trials available to patients in the rural communities in which they live
Cell Therapy and bsAbs	Ability to operationalize FIH-Ph III cell therapy and bsAb studies
Radiotherapy	Ability to operationalize radioligand trials, bringing targeted radiation approaches closer to home for patients.
Hospitalization Capable	Partnered with Ascension Saint Thomas Midtown Hospital (Nashville, TN) to hospitalize research patients
Molecular Profiling	Identifying eligible patients for molecularly-driven trials



GHCR: Our Efficient Single-Site Model

One Pharmacy

- IP is shipped to a central pharmacy and couriered to research clinics.

One PI and IRB submission

- One PI located in either the Nashville or Chattanooga area oversees study activities across clinics.

One Budget and Contract

- Only one budget and contract would need to be completed to allow for faster start-up timelines



TENNESSEE
ONCOLOGY

“I’m not a number. I’m a person here.”

- Extensive-Stage SCLC Research Patient



Thank you for joining us!